Maxim Group Maintains Buy on Compass Pathways, Raises Price Target to $20

COMPASS Pathways Plc Sponsored ADR

COMPASS Pathways Plc Sponsored ADR

CMPS

0.00

Maxim Group analyst Jason McCarthy maintains Compass Pathways (NASDAQ: CMPS) with a Buy and raises the price target from $12 to $20.